Gabelli Healthcare & WellnessRx Trust (N:GRX)

Sector:  Financials Industry:  Closed End Funds
 
See Regulatory Filings on SEC
Company Contact
Address: One Corporate Center
RYE NY 10580-1422
Tel: N/A
Website: N/A
IR: N/A
<
Key People
Mario J. Gabelli
Chairman of the Board of Trustees, Chief Investment Officer
John C. Ball
President, Principal Financial and Accounting Officer, Treasurer
Richard J. Walz
Chief Compliance Officer
Peter D. Goldstein
Vice President, Secretary
David I. Schachter
Vice President
Adam E. Tokar
Vice President
Bethany A. Uhlein
Vice President, Ombudsman
   
Business Overview
The Gabelli Healthcare & WellnessRx Trust (the Fund) is a diversified, closed-end management investment company. The Fund's investment objective is long term growth of capital. It is focused on investing approximately 80% of its assets in equity securities and income producing securities of domestic and foreign companies in the healthcare and wellness industries. The Fund invests in various geographic regions, including North America, Europe, Japan and Asia/Pacific. The Fund's portfolio of investments in various sectors include food; healthcare providers and services; pharmaceuticals; healthcare equipment and supplies; beverages; biotechnology; household and personal products; electronics; specialty chemicals, and food and staples retailing. Gabelli Funds, LLC serves as the investment advisor of the Fund.
Financial Overview
For the fiscal year ended 31 December 2023, Gabelli Healthcare & WellnessRx Trust revenues decreased 2% to $4M. Net income totaled $423K vs. loss of $47.4M. Revenues reflect Dividend- Investment income decrease of 7% to $3.3M. Net Income reflects Unrealized Capital Gains/Losses - Total decrease of 84% to $9.1M (expense), Net realized gain on investments increase of 1% to $11.7M (income).
Reporting Currency: U.S. Dollars
Enterprise value: $203.26M as of Dec 31, 2023
Annual revenue (TTM): $3.98M as of Dec 31, 2023
EBITDA (TTM): -$2.15M as of Dec 31, 2023
Net annual income (TTM): $0.42M as of Dec 31, 2023
Free cash flow (TTM): -$3.33M as of Dec 31, 2023
Net Debt Last Fiscal Year: $53.32M as of Dec 31, 2023
Shares outstanding: 16,679,968 as of Mar 19, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.